Clinical trial
TBTC Study 25: Study of the Tolerability of Higher Doses of Rifapentine in the…
NCT00023426 · Centers for Disease Control and Prevention, U.S. Fed · Completed
Key facts
| NCT number | NCT00023426 |
|---|---|
| Title | TBTC Study 25: Study of the Tolerability of Higher Doses of Rifapentine in the Treatment of Tuberculosis |
| Official title | TBTC Study 25:A Prospective, Randomized, Double-Blind Study of the Tolerability of Higher Doses of Rifapentine |
| Lead sponsor | Centers for Disease Control and Prevention, U.S. Fed |
| Collaborators | US Department of Veterans Affairs U.S. Fed |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Tuberculosis |
| Intervention type | Drug |
| Interventions | rifapentine |
| Enrollment | 150 |
| Start date | Jul 1, 1999 |
| Completion | Feb 1, 2003 |
| First posted | Sep 10, 2001 |
| Last update posted | Sep 13, 2005 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: